For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Magenta Therapeutics, Inc.

USPTO Granted Patents = 14

Forward Citations = 21

Loading Chart...

Loading Chart...

18 inventors (with patents filed for the assignee):

Anthony Boitano (7 out of 14 patents)

Michael P Cooke (5 out of 13 patents)

Rahul Palchaudhuri (5 out of 9 patents)

4. Dwight Morrow (4 out of 4 patents)

5. Adam Hartigan (4 out of 4 patents)

6. Bradley R Pearse (3 out of 6 patents)

7. Sean McDonough (3 out of 6 patents)

8. Rajiv Panwar (3 out of 5 patents)

9. Arthur Glenn Romero (3 out of 38 patents)

10. Andrew Nixon (2 out of 22 patents)

11. Patrick C Falahee (2 out of 2 patents)

12. Kevin A Goncalves (2 out of 2 patents)

13. David Y Jackson (2 out of 18 patents)

14. Edward Ha (2 out of 3 patents)

15. Matthew Duncan Smith (2 out of 2 patents)

14 patents: Sort by Forward Citations

1. 11572411 - Anti-CD117 antibodies and conjugates (2023-02-07),

2. 11260079 - Dosing regimens for the mobilization of hematopoietic stem and progenitor cells (2022-03-01),

3. 11229711 - Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use (2022-01-25),

4. 10919900 - Aryl hydrocarbon receptor antagonists and uses thereof (2021-02-16),

5. 10899843 - Compositions and methods for the depletion of CD117+ cells (2021-01-26),

6. 10882915 - Compositions and methods for the depletion of CD117+ cells (2021-01-05),

7. 10781259 - Modified antibodies and related compounds, compositions, and methods of use (2020-09-22),

8. 10624973 - Methods for the depletion of cells (2020-04-21),

9. 10576161 - Compositions and methods for the depletion of CD137+ cells (2020-03-03),

10. 10457683 - Aryl hydrocarbon receptor antagonists and uses thereof (2019-10-29),

11. 10434185 - Compositions and methods for the depletion of CD137+ cells (2019-10-08),

12. 10351572 - Aryl hydrocarbon receptor antagonists and uses thereof (2019-07-16),

13. 10111966 - Methods for the depletion of CD117+ cells (2018-10-30),

14. 10058573 - Dosing regimens for the mobilization of hematopoietic stem cells (2018-08-28),

Magenta Therapeutics, Inc. is a biotechnology company focused on unlocking the potential of stem cell biology to revolutionize bone marrow transplant for patients with autoimmune diseases, genetic diseases, and blood cancers.With a mission to change the practice of medicine and deliver transformative therapies, Magenta is developing products to bring new hope to patients in need. The company is committed to harnessing the power of stem cells to improve outcomes for patients by creating new transplant options, expanding the use of curative therapies, and providing better access to transplantation.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

14 Patents

#158 in Cambridge, MA

#1,315 in Massachusetts

#21,638 in US

#40,932 in the World

Cambridge, MA, United States of America

Magenta Therapeutics, Inc.

Forward Citations = 21

18 inventors:

Anthony Boitano (7 out of 14 patents)

Michael P Cooke (5 out of 13 patents)

Rahul Palchaudhuri (5 out of 9 patents)

4. Dwight Morrow (4 out of 4 patents)

5. Adam Hartigan (4 out of 4 patents)

Please report any incorrect information to support@idiyas.com

Loading…